HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 12 (December)

1. Antiretroviral therapy in a thousand patients with AIDS in Haiti.
   N Engl J Med, 353(22): 2325-34. [Abstract] [Full-text]
2. Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study.
   Genes Immun, 6(8): 691-8. [Abstract] [Full-text]
3. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression.
   Genes Immun, 6(8): 683-90. [Abstract] [Full-text]
4. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells.
   Nucleic Acids Res, 33(21): 6837-49. [Abstract] [Full-text]
5. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
   Clin Pharmacol Ther, 78(5): 508-19. [Abstract] [Full-text]
6. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
   Pediatrics, 116(6): e846-54. [Abstract] [Full-text]
7. Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation.
   J Infect Dis, 193(1): 45-8. [Abstract] [Full-text]
8. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection.
   J Infect Dis, 193(1): 36-44. [Abstract] [Full-text]
9. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
   J Infect Dis, 193(1): 27-35. [Abstract] [Full-text]
10. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection.
    J Infect Dis, 193(1): 16-26. [Abstract] [Full-text]
11. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study.
    J Infect Dis, 193(1): 9-15. [Abstract] [Full-text]
12. Relation of sexual risks and prevention practices with individuals' stigmatising beliefs towards HIV infected individuals: an exploratory study.
    Sex Transm Infect, 81(6): 511-6. [Abstract] [Full-text]
13. Audio computer assisted interviewing to measure HIV risk behaviours in a clinic population.
    Sex Transm Infect, 81(6): 501-7. [Abstract] [Full-text]
14. Factors associated with HIV testing among black Africans in Britain.
    Sex Transm Infect, 81(6): 494-500. [Abstract] [Full-text]
15. HIV in female sex workers in five border provinces of Vietnam.
    Sex Transm Infect, 81(6): 477-9. [Abstract] [Full-text]
16. Relation between the HIV and the re-emerging syphilis epidemic among MSM in Germany: an analysis based on anonymous surveillance data.
    Sex Transm Infect, 81(6): 456-7. [Abstract] [Full-text]
17. Declining syphilis prevalence among pregnant women in northern Botswana: an encouraging sign for the HIV epidemic?
    Sex Transm Infect, 81(6): 453-5. [Abstract] [Full-text]
18. Risk of HIV/AIDS in China: subpopulations of special importance.
    Sex Transm Infect, 81(6): 442-7. [Abstract] [Full-text]
19. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.
    BMJ, 331(7529): 1368. [Abstract] [Full-text]
20. Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus.
    J Mol Biol, 355(1): 157-68. [Abstract] [Full-text]
21. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries.
    BMJ, 331(7530): 1431-7. [Abstract] [Full-text]
22. High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting.
    Trop Med Int Health, 10(12): 1242-50. [Abstract] [Full-text]
23. Review editorial: prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment.
    Trop Med Int Health, 10(12): 1209-14. [Abstract] [Full-text]
24. Expectant management of anal squamous dysplasia in patients with HIV.
    Dis Colon Rectum, 49(1): 36-40. [Abstract] [Full-text]
25. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis.
    Vaccine, 24(3): 272-9. [Abstract] [Full-text]
26. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
    Proc Natl Acad Sci U S A, 102(51): 18514-9. [Abstract] [Full-text]
27. Analysis of the influence of subcellular localization of the HIV Rev protein on Rev-dependent gene expression by multi-fluorescence live-cell imaging.
    Exp Cell Res, 312(4): 443-56. [Abstract] [Full-text]
28. Structural polymorphism of the HIV-1 leader region explored by computational methods.
    Nucleic Acids Res, 33(22): 7151-63. [Abstract] [Full-text]
29. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.
    Lancet Infect Dis, 6(1): 53-9. [Abstract] [Full-text]
30. Barriers to participation in HIV drug trials: a systematic review.
    Lancet Infect Dis, 6(1): 32-8. [Abstract] [Full-text]
31. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source.
    J Virol, 80(2): 1047-52. [Abstract] [Full-text]
32. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.
    J Virol, 80(2): 999-1014. [Abstract] [Full-text]
33. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    J Virol, 80(2): 875-82. [Abstract] [Full-text]
34. R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.
    J Virol, 80(2): 854-65. [Abstract] [Full-text]
35. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.
    J Virol, 80(2): 835-44. [Abstract] [Full-text]
36. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.
    J Virol, 80(2): 802-9. [Abstract] [Full-text]
37. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
    J Virol, 80(2): 750-8. [Abstract] [Full-text]
38. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.
    J Virol, 80(2): 571-7. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.